Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells

The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation

(2018) Wenwen Xu et al.   Cellular & Molecular Immunology

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

(2017) Vikram R. Juneja et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

(2017) Takuro Noguchi et al.   Cancer Immunology Research

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

(2017) Jan Willem Kleinovink et al.   OncoImmunology

Coinhibitory Pathways in Immunotherapy for Cancer

(2016) Susanne H. Baumeister et al.   Annual Review of Immunology

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library

(2016) Longlong Luo et al.   Cellular & Molecular Immunology

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

(2015) R. Stewart et al.   Cancer Immunology Research

Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses

(2014) Xuanming Yang et al.   CANCER CELL

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA